The Rx Recap: August 17-22

Welcome to this week’s roundup of the most insightful and impactful articles from the sister publications of Dermatology Times, all under One MJH Life Sciences. Our network brings together expert perspectives, clinical advancements, and industry updates to keep clinicians informed and ahead of the curve. From cutting-edge treatments to practice management strategies, here’s a look at the top stories shaping the field of medicine.

Perceptions of Dermatologic AEs Could Impact Treatment Adherence

Cancer Network reports on a survey highlighting how perceptions of dermatologic adverse effects (AEs) from anti-cancer therapies may influence treatment decisions. Conducted in an underserved area of Washington, DC, the study found that many respondents—both with and without prior cancer experience—believed therapies commonly caused hair loss, rashes, and nail changes, with some indicating they might forego treatment because of these effects. The findings underscore the need for greater education, interdisciplinary collaboration, and accessible patient resources to reduce treatment avoidance and improve adherence.

New Machine-Learning Approach Could Speed Precision Drug Development

Medical Devices and Technology reports that researchers in Austria have developed a deep learning platform, Molecular Surface Interaction Fingerprinting (MaSIF), that could transform precision therapy design. The system uses geometric deep learning to engineer custom proteins that bind only to drug-protein complexes, offering new opportunities for safer and more controlled immunotherapies. In proof-of-concept tests, MaSIF-designed binders successfully recognized targets including progesterone, Venetoclax, and Actinonin, underscoring its potential to accelerate the development of next-generation biologics.

Navigating the New Wave of Packaging Regulations

Nutritional Outlook reports that food and dietary supplement companies face new challenges as states adopt Extended Producer Responsibility (EPR) laws, shifting packaging waste management costs from municipalities to producers. While compliance can be complex—requiring registration, detailed reporting, and eco-modulated fees—early engagement offers opportunities to cut costs, drive sustainable innovation, and strengthen consumer trust. With states like California, Oregon, and Maine already implementing EPR and others considering similar measures, brands must prepare for a rapidly changing regulatory landscape.

Adolescent Type 1 Diabetes Incidence and Prevalence Rising Globally Since 1990

HCPLive reports that global incidence and prevalence of type 1 diabetes (T1D) in children under 14 have risen by 32% and 41%, respectively, between 1990 and 2021, largely driven by population growth and improved epidemiological tracking. Using Global Burden of Disease 2021 data, investigators found that while T1D-related disability-adjusted life years and mortality decreased over the same period, disparities remain across sociodemographic regions. Researchers emphasized the need for more precise measures of health inequality and called for targeted strategies to improve access, policy efficiency, and long-term disease control worldwide.

Under-eye filler: Cannula vs needle in tear trough treatment

Ophthalmology Times highlights that while tear trough filler remains debated due to risks like edema, festoons, and vascular compromise, it continues to serve as an effective, nonsurgical option for under-eye rejuvenation when performed with precision and restraint. Hyaluronic acid filler can restore volume and reduce shadowing in carefully selected patients, offering a reversible, outpatient alternative to surgery. Success depends on meticulous anatomical knowledge, patient selection, and conservative dosing, underscoring the balance between safety and natural results.

Want to read more on specialty care, pharmacy, industry sciences, and more? Check out MJH Life Sciences full list of brands here.